VMAT1 Protein

VMAT1 Protein

Introduction

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">VMAT1 Protein</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>VESICULAR-MONOAMINE-TRANSPORTER-1</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>VMAT1</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Protein</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/?query=VESICULAR-MONOAMINE-TRANSPORTER-1" target="_blank">Search UniProt</a></td>
</tr>
</table>

VMAT1 (Vesicular Monoamine Transporter 1) is encoded by the SLC18A1 gene and is responsible for transporting monoamine neurotransmitters into synaptic vesicles. This transporter is essential for proper monoaminergic neurotransmission and plays important roles in neurodegenerative diseases.

Overview

VMAT1 Protein

Introduction

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">VMAT1 Protein</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>VESICULAR-MONOAMINE-TRANSPORTER-1</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>VMAT1</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Protein</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/?query=VESICULAR-MONOAMINE-TRANSPORTER-1" target="_blank">Search UniProt</a></td>
</tr>
</table>

VMAT1 (Vesicular Monoamine Transporter 1) is encoded by the SLC18A1 gene and is responsible for transporting monoamine neurotransmitters into synaptic vesicles. This transporter is essential for proper monoaminergic neurotransmission and plays important roles in neurodegenerative diseases.

Overview

VMAT1 is located on chromosome 8p21.3 and encodes an integral membrane protein that uses a proton gradient to transport monoamine neurotransmitters into synaptic vesicles. The transporter is essential for packaging dopamine, norepinephrine, epinephrine, serotonin, and histamine into vesicles for regulated release during neurotransmission. [@liu2022]

Key Points: [@guillot2009]

• Gene: SLC18A1 (chromosome 8p21.3)
• Protein Class: Vesicular monoamine transporter (VMAT)
• Protein Size: 525 amino acids
• Primary Localization: Synaptic vesicle membrane of monoaminergic [neurons](/entities/neurons)
• Substrates: Dopamine, norepinephrine, epinephrine, serotonin, histamine
• Disease Associations: Depression, bipolar disorder, neurodegenerative diseases
• Therapeutic Relevance: Target for VMAT inhibitors, drug delivery

Molecular Structure

The VMAT1 protein has several key structural features: [@fon1997]

• 12 transmembrane domains: Form the transporter pore
• Vesicular H+-ATPase binding site: Uses proton gradient for transport
• Monoamine binding pocket: Recognizes various monoamine substrates
• Cytoplasmic loops: Contain regulatory domains

Function

VMAT1 transports monoamine neurotransmitters from the cytoplasm into synaptic vesicles: [@lohr2020]

Monoamine (cytoplasm) + H+ (vesicle lumen) → Monoamine (vesicle) + H+ (cytoplasm) [@wang1997]

This proton-gradient dependent transport requires: [@takahashi2021]

• Vesicular H+-ATPase: Generates the proton gradient
• ATP: Powers the proton pump
• Mg2+: Required cofactor

Biological Significance

VMAT1 is crucial for:

• Neurotransmitter storage: Packages monoamines into vesicles for regulated release
• Neuroprotection: Sequesters toxic monoamines away from cytosolic enzymes
• Synaptic transmission: Enables quantal release of neurotransmitters
• Monoamine homeostasis: Regulates intracellular monoamine levels

Tissue Distribution

VMAT1 is expressed in:

• Sympathetic nerve terminals
• Adrenal medulla chromaffin cells
• Central nervous system (lower expression than VMAT2)
• Peripheral nervous system

Disease Associations

Psychiatric Disorders

• Depression: SLC18A1 polymorphisms associated with depression risk
• Bipolar Disorder: Some variants linked to mood disorders
• Schizophrenia: Altered monoamine transport in some studies

Neurodegenerative Diseases

Parkinson's Disease

• VMAT2 (not VMAT1) is the primary therapeutic target
• VMAT2 inhibitors like tetrabenazine treat chorea
• Both VMATs relevant to dopamine handling

Alzheimer's Disease

• Monoaminergic dysfunction contributes to cognitive symptoms
• VMAT expression may be altered in AD

Therapeutic Relevance

VMAT1 is a target for several therapeutic approaches:

Note: Most CNS drugs target VMAT2 rather than VMAT1.

Research Directions

Current research focuses on:

• Understanding VMAT gene variants and neuropsychiatric disease
• Developing selective VMAT modulators
• Investigating VMAT dysfunction in neurodegeneration
• Exploring gene therapy approaches

See Also

• [VMAT2](/genes/vmat2)
• [SLC18A1](/genes/slc18a1)
• [SLC18A2](/genes/slc18a2)
• [Dopamine](/entities/dopamine)
• [Norepinephrine](/entities/norepinephrine)
• [Synaptic Vesicles](/entities/synaptic-vesicles)
• [Parkinson's Disease](/diseases/parkinsons-disease)

Background

The study of Vmat1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

External Links

• [SLC18A1 Gene - NCBI](https://www.ncbi.nlm.nih.gov/gene/6570)
• [VMAT1 - UniProt](https://www.uniprot.org/uniprot/Q8TFQ2)
• [VMAT2 - UniProt](https://www.uniprot.org/uniprot/Q05940)

References